



Hope in Action: An EL-PFDD Meeting on Angelman Syndrome

April 7, 2025 | 10:00 a.m. to 3:00 p.m. ET

Meeting Agenda

10:00-10:05 a.m.	Welcome <i>Tim Franson, MD, Moderator</i> <i>Principal, Faegre Drinker Consulting</i>
10:05-10:15 a.m.	Opening Remarks <i>Amanda Moore</i> <i>Chief Executive Officer</i> <i>Angelman Syndrome Foundation</i> <i>Ryan Fischer</i> <i>Chief Operating Officer</i> <i>Foundation for Angelman Syndrome Therapeutics</i>
10:15-10:25 a.m.	Overview of Patient-Focused Drug Development <i>Michelle Campbell, PhD</i> <i>Associate Director, Stakeholder Engagement & Clinical Outcomes</i> <i>Office of Neuroscience</i> <i>Center for Drug Evaluation and Research</i> <i>Food and Drug Administration</i>
10:25-10:35 a.m.	Overview of Angelman Syndrome Symptoms <i>Ron Thibert, DO, MSPH</i> <i>Director, Angelman Syndrome Clinic</i> <i>Massachusetts General Hospital for Children</i>
10:35-10:45 a.m.	Discussion Format Overview and Demographic Polling <i>Tim Franson, Meeting Moderator</i>
Topic 1: Symptoms of Angelman Syndrome and Impact on Daily Life	
10:45-11:10 a.m.	Panel Remarks from Caregivers of People with Angelman Syndrome
11:10 am.-12:30 p.m.	Polling and Facilitated Discussion
12:30-1:00 p.m.	Break

1:00-1:10 p.m. **Overview of Angelman Syndrome Treatment Approaches**
Elizabeth Berry-Kravis MD, PhD
Director, F.A.S.T. Center for Translational Research
Rush University Medical Center

Topic 2: Views on Current Approaches to Treatment and Future Treatments

1:10-1:35 p.m. **Panel Remarks from Caregivers of People with Angelman Syndrome**

1:35-2:45 p.m. **Polling and Facilitated Discussion**

2:45-2:55 p.m. **Pre-Meeting Survey Data Presentation**
Ryan Fischer
Chief Operating Officer
Foundation for Angelman Syndrome Therapeutics

2:55-3:00 p.m. **Closing Remarks**
Tim Franson, Moderator